The Manchester spinout is seeking capital to launch its first product, a test that can detect the early-stage onset of an eye disease called age-related macular degeneration.
MuMac, a UK-based medical device spinout based on University of Manchester research, is in the process of raising a funding round that would support the launch of its first product.
Founded in November 2016, MuMac has created optical technology for the rapid screening of eye diseases. The company’s first product is an instrument called Rapida, which offers a test to detect age-related macular degeneration, which may result in blurred vision or blindness.
The money will support the commercial launch of Rapida, which can detect the disease even before any biological changes that can be identified through imaging devices, and the research and development of other ophthalmology diagnostics.
MuMac’s technology is based on research by Ian Murray, now chief scientific officer, Jeremiah Kelly and David Carden.
UMI3, the university’s tech transfer office, has been supporting MuMac’s research for more than three years and is set to transfer all related intellectual property in the near future.
